FDA approves expanded dosing regimen for Kyowa Kirin’s Crysvita in adult XLH

Edited by Robert McTiernan··3 min read

Japan’s Kyowa Kirin, Inc. (JPX: 4151.T) has received US FDA approval for an updated dosing regimen for Crysvita (burosumab-twza) in adults with X-linked hypophosphatemia (XLH), a rare genetic disorder characterized by impaired phosphate reabsorption and progressive skeletal disease. The label update allows clinicians to escalate both dose and frequency for adult patients who do not achieve normal serum phosphorus levels on the standard regimen, adding a flexible titration pathway to an indication where Crysvita remains the only approved targeted therapy.

The revised prescribing information permits a stepwise escalation from the standard every-four-week schedule. Adults with serum phosphorus below the normal range after the initial treatment period may be transitioned to 0.5 mg/kg, not to exceed 90 mg, administered once every two weeks. If phosphorus levels remain subtherapeutic after four weeks at that dose, clinicians may further increase to 1 mg/kg, again capped at 90 mg every two weeks. The update does not alter the approved indication, which covers XLH in adult and pediatric patients aged six months and older.

Burosumab-twza is a recombinant, fully human monoclonal IgG1 antibody that binds to and inhibits fibroblast growth factor 23 (FGF23), the protein produced in excess in XLH that drives renal phosphate wasting. By blocking FGF23 activity, the drug restores renal phosphate reabsorption and increases circulating levels of active vitamin D, addressing the underlying hormonal dysregulation rather than transiently supplementing phosphate as conventional therapy does.

The clinical evidence base supporting Crysvita’s use in adults includes trials registered in the burosumab program, which spans 62 studies across the development program. The pivotal adult Phase III trial evaluated burosumab against placebo in adults with XLH, with serum phosphorus normalization as a primary endpoint. Data from that trial demonstrated statistically meaningful increases in serum phosphorus and improvements in markers of bone mineralization. The current dosing label update reflects post-approval clinical experience indicating that a subset of adult patients does not sustain adequate phosphorus levels on the every-four-week schedule, supporting the need for an individualized titration option.

The AllSci BriefSystematic R&D and deal news. Daily.

Prior to the 2023 transition of US commercial leadership from Ultragenyx Pharmaceutical to Kyowa Kirin, Inc., burosumab was co-developed under a global collaboration between the two companies. Kyowa Kirin, which discovered the molecule internally under the code KRN23, now holds full commercial responsibility for Crysvita in the United States and Canada.

The XLH treatment landscape remains notably sparse. Before burosumab’s initial approval, the standard of care consisted of oral phosphate supplementation combined with active vitamin D analogues such as calcitriol — a regimen that requires multiple daily doses, carries a risk of nephrocalcinosis with prolonged use, and does not target the underlying FGF23 excess. Crysvita holds the only FDA-approved label specifically for XLH, and no late-stage pipeline competitor targeting the same mechanism has reached Phase III in this indication. The expanded dosing flexibility may be relevant for clinicians managing patients who have suboptimal biochemical responses on the standard schedule, without requiring a switch to conventional therapy.

The approval carries implications for how rare endocrine bone diseases are managed in adults, a population in whom persistent hypophosphatemia contributes to osteomalacia, fracture risk, and impaired mobility. The ability to titrate within the existing drug class, rather than defaulting to off-label phosphate supplementation, reflects a broader trend toward individualized dosing in rare disease settings where patient heterogeneity in drug response is well documented but has historically been difficult to accommodate within a single approved regimen.

This article was generated with AI assistance and reviewed and edited by the AllSci editorial team Explore more at AllSci News: https://allsci.com/news/